Abstract:
Some people are born without pain and carry a rare genetic mutation. In the past, people wanted to reproduce this painless feeling with drugs, but the effect was not good. According to the latest news on the website of University College London, researchers at University College London have finally found a painless recipe by using transgenic technology to let mice carry such genes.

In 2006, researchers found that the sodium channel, Nav1.7, was particularly critical in the pain signaling pathway, and that those who were born with no pain perception had a failure of the Nav1.7 channel. However, the development of drugs to block Nav1.7, the analgesic effect is disappointing.

This time, the researchers divided the mice in the same nest into two groups: the transgenic group and the control group, and let the transgenic mice carry the human painless variant gene. The results showed that in the nervous system of transgenic mice, the concentration of opioids produced by itself was about twice that of the control group.

To test the importance of opioids in painlessness, researchers used naloxone, an opioid blocker, to mice lacking Nav1.7 and found that they felt pain again. The researchers then gave naloxone to a 39 year old woman with the variant, and she developed pain for the first time.

John wood, senior author of the paper, said: "after nearly 10 years of disappointing drug experiments, now we have confirmed that Nav1.7 is indeed a key factor in human pain, and the secret ingredient is the ancient opioid peptide. We have applied for a patent by combining low-dose opioids with Nav1.7 blockers. This is expected to recreate the painless experience experienced by those who carry the rare variant gene, which we have successfully tested in ordinary mice. "

Broad-spectrum sodium channel blockers are not suitable for long-term pain control. They can cause complete numbness and serious side effects. Opioid analgesics, such as morphine, are very effective for pain relief, but long-term use will produce drug dependence and drug resistance.

"In combination with the Nav1.7 blocker, the amount of opioid needed to suppress pain is very low." "People who fail with Nav1.7 will produce low concentrations of opioids throughout their lives without developing resistance or unpleasant side effects," wood explained. We hope that this method can be used in human experiments in 2017 to help millions of chronic pain patients around the world. "

Shengnuo bio PRODUCT

Best sales manager contact

About Shengnuo

Chengdu Shengnuo Biotechnology Co., Ltd. has "Chengdu polypeptide drug engineering technology research center" in Chengdu, mainly engaged in polypeptide, polypeptide drug and beauty peptide research. Our zero defect has passed the FDA certification, and now it has become the first-class professional peptide drug and product development, technology transfer, technical service and peptide drug industry in the scale production and export of China's parks.